Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Rockx, Barry
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Corti, Davide
    • Other Affiliation: Institute for Research in Biomedicine
  • Donaldson, Eric
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
  • Sheahan, Timothy
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
  • Stadler, Konrad
    • Other Affiliation: Novartis Vaccines
  • Lanzavecchia, Antonio
    • Other Affiliation: Institute for Research in Biomedicine
  • Baric, Ralph
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
Abstract
  • Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic and epidemiological analyses have suggested that it originated from animals. The spike (S) glycoprotein has been identified as a major component of protective immunity, and 23 different amino acid changes were noted during the expanding epidemic. Using a panel of SARS-CoV recombinants bearing the S glycoproteins from isolates representing the zoonotic and human early, middle, and late phases of the epidemic, we identified 23 monoclonal antibodies (MAbs) with neutralizing activity against one or multiple SARS-CoV spike variants and determined the presence of at least six distinct neutralizing profiles in the SARS-CoV S glycoprotein. Four of these MAbs showed cross-neutralizing activity against all human and zoonotic S variants in vitro, and at least three of these were mapped in distinct epitopes using escape mutants, structure analyses, and competition assays. These three MAbs (S109.8, S227.14, and S230.15) were tested for use in passive vaccination studies using lethal SARS-CoV challenge models for young and senescent mice with four different homologous and heterologous SARS-CoV S variants. Both S227.14 and S230.15 completely protected young and old mice from weight loss and virus replication in the lungs for all viruses tested, while S109.8 completely protected mice from weight loss and clinical signs in the presence of viral titers. We conclude that a single human MAb can confer broad protection against lethal challenge with multiple zoonotic and human SARS-CoV isolates, and we identify a robust cocktail formulation that targets distinct epitopes and minimizes the likely generation of escape mutants.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Journal of Virology
Journal volume
  • 82
Journal issue
  • 7
Page start
  • 3220
Page end
  • 3235
Language
  • English
ISSN
  • 0022-538X

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 2377-07.pdf 2020-04-03 Public Download